Corvus Pharmaceuticals Inc expected to post a loss of 18  cents a share - Earnings Preview

Corvus Pharmaceuticals

29/07/2022 12:45

* Corvus Pharmaceuticals Inc  CRVS.OQ   CRVS.O  is expected
to show no change in quarterly revenue when it reports 
results on August 1. 
    * ​Refinitiv's mean analyst estimate for Corvus
Pharmaceuticals
Inc is for a loss of 18 cents per share. For the same quarter
last year, the company reported a loss of 28 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Corvus
Pharmaceuticals Inc is $7​, above​ its last closing price
of $0.89. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2022  -0.15       -0.15      -0.18     Missed  -17.4
 Dec. 31 2022  -0.18       -0.19      -0.20     Missed  -6.7
 Sep. 30 2021  -0.24       -0.26      -0.24     Beat    6.5​
 Jun. 30 2021  -0.31       -0.32      -0.28     Beat    11.6
 ​​Mar.        -0.31       -0.31      -0.34     Missed  -9.7
 31 2021                                                
 Dec. 31 2020  -0.33       -0.32      -0.33     Missed  -2.3​
 Sep. 30 2020  -0.22       -0.24      -0.33     Missed  -37.5
 Jun. 30 2020  -0.30       -0.28      -0.36     Missed  -30.4
 This summary was machine generated July 29 at 11:45 GMT.  All
figures in US dollars  unless otherwise stated